Clinical trial · Interventional
To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial
NCT00191191CI-TRIAL-00002871completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pemetrexed 1000 mg/m2 | Drug | Pemetrexed | ALIAS |
| Pemetrexed 500 mg/m2 | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pemetrexed 500 mg/m2
- description
- Pemetrexed 500 mg/m2
- interventionNames
- Drug: Pemetrexed 500 mg/m2
- type
- EXPERIMENTAL
- label
- Pemetrexed 1000 mg/m2
- description
- Pemetrexed 1000 mg/m2
- interventionNames
- Drug: Pemetrexed 1000 mg/m2
Primary outcomes (1)
- measure
- Best Overall Response
- timeFrame
- baseline to measured progressive disease (up to 3.2 years)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical stage III or IV * Previously treated with one or two chemotherapeutic regimens * Performance status: 0-2 Exclusion Criteria: \- Inability or unwillingness to take folic acid or vitamin B12 supplementation
References
Publications (0)
Data not yet available
No reference posted for this study.